By Tony MauroContactAll ArticlesThe National Law JournalJune 17, 2013The Supreme Court gave something to both sides in a closely watched dispute over so-called "pay to delay" agreements between brand-name and generic drug manufacturers that put off the production of generics in return for payments by brand-name patent holders.
This article requires free registration to Law.com. Please sign in or register to read the full text.
No comments:
Post a Comment